{"schema_version":"secwatch.filing_event.v1","accession":"0001818331-22-000044","form_type":"8-K","ticker":"WGS","cik":"0001818331","company_name":"GeneDx Holdings Corp.","filed_at":"2022-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:04:02.475618+00:00","generated_at":"2026-06-25T19:07:25.229321+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sema4 Q1 2022: revenue $53.9M, net loss $76.9M; closes GeneDx acquisition, raises cash burn savings to $50M","bullets":["Total revenue $53.9M (incl. COVID-19); ex-COVID revenue $50.1M, up 4% YoY.","Adjusted gross margin 13%, up ~1,300 bps sequentially; net loss $76.9M, adjusted net loss $65.5M.","Completed GeneDx acquisition in April; $200M private placement closed with Pfizer among investors.","Reaffirms FY2022 pro forma revenue target $350M; total revenue guidance $305-315M.","Cash $315M as of March 31; expects to reduce 2022 cash burn by $50M, extending runway into 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001818331-22-000044","json":"https://secwatch.observer/filing/0001818331-22-000044.json","markdown":"https://secwatch.observer/filing/0001818331-22-000044.md","text":"https://secwatch.observer/filing/0001818331-22-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818331/000181833122000044/0001818331-22-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818331/000181833122000044/smfr-20220512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T19:07:25.229321+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}